NeuroDex, Inc., a Natick, Mass.-based developer of diagnostics, theranostics, prognostics, and pharmacodynamic analysis in the neurology space, completed its seed round of financing of undisclosed amount.
The round was led by ICV Venture Engineering Fund I.
The company intends to use the funds to build out, expand, and streamline its ExoSORT™ technology.
Led by Oded Biran, Co-Founder and Chief Executive Officer, NeuroDex is a developer of exosome-of-origin based diagnostics. Building on all of its proprietary platform technologies (including ExoSORT™), the company develops a full range of exosome-of-origin, minimally invasive, blood-based diagnostic, prognostic, pharmacodynamic, and theranostic tools.